Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 23.9% | 48.7% | 122.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 81.9% | 82.5% | 79.5% | 73.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -6.9% | -14.5% | -62.9% | -229.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -27% | -38% | -85.9% | -247.5% |
| EPS Diluted | -0.37 | -0.45 | -0.7 | -1.55 |
| % Growth | 17.8% | 35.7% | 54.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |